9 100+ discovery programs Therapeutic areas 125+ Programs across US and EU, Aspire to deliver > 100 small molecule clinical candidates by 2025. Averaging 10+ years of collaborative and strategic partnerships with clients. 80+ diverse customers across big and mid-size pharma, biotechs and startups. Specialization in synthesis and medicinal chemistry aided by high quality biology, DMPK, toxicology, cGMP scale up and formulation services. Delivering complex chemical synthesis from development to commercialization. 700 Strong global R&D team across Hyderabad and Manchester, UK. 19 molecules handled from clinical phases to commercialization, 40+ projects following QbD approach. 29 Process validation completed comprising 18 APIs and 11 Intermediates. Production of high-quality APIs and intermediates that cater to highly regulated markets such as the US, Europe and Japan. USFDA and PMDA inspected facilities. 450 kiloliters manufacturing capacity, up to 25kg dedicated facility for early phase supplies and 25 tonnes commercial production scale of molecules. Dedicated Process Safety lab for evaluations throughout the product lifecycle. 9 CNS 15% Anti-viral 15% Inflamation 10% Oncology 50% Misc. 10% EU & UK 15% Asia 5% USA 80% Complex chemical synthesis from development to commercialization Discovery services spanning the entire journey from target ID and validation to IND
RkJQdWJsaXNoZXIy MTIwMDc4NQ==